MedeSol Global, Inc. — SEC Form D Filing

MedeSol Global, Inc. filed an SEC Form D on August 31, 2026, reporting $25K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
August 31, 2026
Amount reported
$25K
Round stage
Seed
Industry
Biotechnology
Website
https://medesolglobal.com/

What the company does

Securities: Simple Agreement for Future Equity (SAFE). Revenue: $1 - $1,000,000. Exemption: Rule 506(b). Incorporated: NEVADA

Problem

For a century, hypochlorous acid (HOCl) has been limited by two challenges: it could not be made at scale, stable and pure, and its solutions were short-lived once dried. This prevented its widespread use despite its powerful antimicrobial properties.

Solution

MedeSol Global has developed two proprietary chemistry platforms to overcome these limitations: one that generates pure, stable HOCl at scale, and another that allows HOCl to persist and remain effective long after it dries, enabling its use in various products and applications.

Why now

The World Health Organization (WHO) added HOCl to its Model List of Essential Medicines in 2025 as a disinfectant, validating its importance and effectiveness as a safer alternative to other chlorine-based disinfectants.

Verdict

This cleared because it presented a foundational technology unlock for a validated chemical, not because it articulated a clear, immediate market wedge. Investors implicitly bet on the team's ability to navigate the complex regulatory and commercialization pathways required to scale a novel chemical platform. The limited upside stemmed from the long development cycles and substantial capital requirements typically associated with bringing new chemical formulations to market, which could dilute early returns.

Source: SEC EDGAR Form D filing